Arrowhead’s new Redemplo findings in severe hypertriglyceridemia have analysts split

Safety and dosing are likely to be “key differentiators” for Arrowhead Pharmaceuticals as it looks to challenge Ionis Pharmaceuticals’ lead in the severe hypertriglyceridemia market.